However, p53 also has detrimental effects on tumor therapy due to the presence of multiple resistance mechanisms, particularly two pathways associated with antioxidant defense—the p53/immediate-early response 5 (IER5)/heat shock factor 1 (HSF1) axis and the p53/p21/NRF2 axis [104]. This evidence concerns the gene IER5 and neoplasm.